Overview

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI. Omniscan will be administered intravenously at the medical discretion of the prescribing physician.

Phase:

Phase 4

Details

Lead Sponsor:

GE Healthcare

Collaborator:

i3 Statprobe